top of page

Program Description


The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 22nd year, is a unique and exciting multidisciplinary CME conference. The Congress has become the premier global meeting dedicated to diabetes, obesity, lipids, cardiovascular-kidney, and liver disease linking basic research to clinical practice in pursuit of our theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.

WCIRDC 2024 will return to a live, in-person meeting at the Hilton Universal City Hotel in Los Angeles, on

December 12-14, 2024.

WCIRDC is the only meeting of its size combining basic and clinical science. For nearly two decades it has brought researchers, physicians, clinicians, and other healthcare professionals together for a distinctive international program that bridges the latest developments from bench-to-bedside-to-bench. “I heard it first at the Congress” is a frequent remark from the audience. WCIRDC offers attendees a unique experience to interact with the distinguished global faculty. In an intimate setting, for a collaborative experience that explores the newest understanding of metabolic diseases and the development of future therapeutic modalities. 

Since Dr. Gerald Reaven’s pioneering work crystallized the relationship between insulin resistance (IR), diabetes, obesity, and CVD, Congress’ focus has expanded to cover the kidney, liver, brain, bone, cancer, and more.  The congress addresses dyslipidemia, atherosclerosis, hypertension, hypercoagulation, inflammation, and energy metabolism. It provides the newest clinical updates on pharmaceutical interventions such as GLP1ra, SGLT2i’s, PCSK9i’s, MRA, and EPA to name a few. The goal is to understand the state-of-the-art pathophysiology, and new medical interventions, and to develop appropriate comprehensive clinical management strategies.


To make basic and clinical research topics relevant to clinical medicine, following each session there will be a live Q&A and a discussion on implications to clinical practice. To promote more interaction with faculty and provide further insights, each day will end with one hour of the live panel, providing a summary of the day, commentary, and opening for Q&A.


The Congress attracts state-of-the-art abstracts attracting, young up-and-coming researchers as well as recognized leaders from around the globe. The abstracts will be published in Metabolism, a peer-reviewed journal, and will also be available for 90 days on demand.


The congress is featured by many media outlets with proceedings featured in global medical news venues such as Healio, Medscape, Endocrinology & Cardiology Today, Clinical Endocrinology News, Practical Cardiology, HCP Live, and more, while articles are being published in peer-reviewed journals like Journal of Diabetes, Endocrine Practice, Metabolism, Diabetes & Vascular Disease Research, Diabetes, and its complications and others.


Program Objectives

The program is designed to evaluate both clinical and basic science aspects of diabetes, obesity, CVD, and CKD, focusing on insulin resistance, incretins, the gut, the brain, the kidney, and the heart. The goal is to understand the pathophysiology and develop appropriate comprehensive clinical management plans.

Upon completion of this meeting, participants should be able to:

  • Describe the relationship between diabetes, obesity, kidney disease, and heart disease

  • Implement best practices for the prevention and management of CKD, HF, and CVD

  • Describe the recommended uses of SGLT2 inhibitors for the treatment of HF

  • Understand the contemporary role of SGLT2 inhibitors in CKD with and without diabetes

  • Describe the benefits of GLP1-RAs in patients with ASCVD or at risk of ASCVD events

  • Evaluate the evidence supporting the use of new and emerging therapies to reduce cardiovascular mortality in patients with cardiometabolic disease

  • Explain the roles of diabetes and insulin resistance in the development of CKD, HF, and CVD

  • Evaluate the impact on the clinical practice of new CVOTs in patients with diabetes and cardiometabolic diseases

  • Discuss the effects of insulin resistance on the heart, kidney, and liver

  • Design therapeutic regimens for patients with multiple cardiometabolic and renal disorders that capitalize on agents with broad effects across the spectrum of these comorbidities

  • Utilize technology to enhance the effectiveness of therapeutics

  • Describe the direct and indirect impact of the COVID-19 pandemic on patient health



Target Audience

This educational initiative is designed for endocrinologists, cardiologists, nephrologists, family physicians, internists, diabetologists, gastroenterologists, pediatricians, OB/GYN, researchers, nurse practitioners, physician assistants, dieticians, diabetes educators, and other healthcare professionals interested in the pathophysiology, prevention, and treatment of diabetes, obesity, CVD, CKD, HF, and associated conditions, as well as the effect of these conditions on health and society.

Program Chair

Yehuda Handelsman, MD is an Endocrinologist with extensive experience in the clinical aspect of Diabetes and CVD and is well-versed in managing Hyperglycemia, HTN, Lipid disorders, and coagulation.

Dr. Handelsman is also an experienced clinical researcher and educator.

Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE

Medical Director & Principal Investigator, Metabolic Institute of America
President, Diabetes, CardioRenal & Metabolism Institute (DCMi)
Chair & Program Director, WCIRDC
Tarzana, California 

bottom of page